FDA has cleared Boston Scientific Corp.'s AngioJet Ultra Console with its ZelanteDVT thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins. The company says the console and catheter offer more power to break up large clots in peripheral veins compared to the previous iterations. The device will potentially decrease procedural times, relieving symptoms faster and reducing late-stage complications.
ZelanteDVT is the first AngioJet catheter designed specifically to treat DVT, a condition it says is estimated to affect up to 2.5 million people in the US and Europe annually....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?